Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Conexeu SciencesCNXU -9.91%12 Dividend Yield % is 0.00% as of Aug. 10, 2026. GuruFocus rates CNXU with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, Conexeu Sciences ranks worse than 666666% on this metric.
As of today (2026-08-10), the Trailing Annual Dividend Yield of Conexeu Sciences is 0.00%.
The historical rank and industry rank for Conexeu Sciences's Dividend Yield % or its related term are showing as below:
CNXU's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.265 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Conexeu Sciences's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNXU vs GALT, SRZN, RNAC: Dividend Yield % Comparison
For the Biotechnology subindustry, Conexeu Sciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Conexeu Sciences Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Conexeu Sciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Conexeu Sciences's Dividend Yield % falls into.
Conexeu Sciences (CNXU) has a Dividend Yield % of 0.00% as of Aug. 10, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Conexeu Sciences and its competitors. According to the industry distribution chart, Conexeu Sciences ranks #999999 out of 150 companies in the Biotechnology industry.
Is Conexeu Sciences' Dividend Yield % too high?
Conexeu Sciences' current Dividend Yield % is 0.00%. Based on the distribution chart, Conexeu Sciences ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Conexeu Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Conexeu Sciences' Dividend Yield % compare to GALT and SRZN?
According to the Biotechnology industry distribution chart, Conexeu Sciences ranks #999999 out of 150 companies for Dividend Yield %. This places Conexeu Sciences in the lower half of its industry. The industry median Dividend Yield % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.27, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Conexeu Sciences and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Conexeu Sciences's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conexeu Sciences stock overvalued right now?
Conexeu Sciences (CNXU) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Conexeu Sciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Conexeu Sciences (CNXU), the current Dividend Yield % is 0.00% as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
12GF Score
Get the complete analysis for CNXU
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNXU has been successfully added to your 
